etrumadenant

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing next-generation cancer therapies by targeting important biological pathways in the tumor microenvironment. The company's pipeline includes a diverse range of small molecules and antibodies designed to modulate the adenosine pathway, the TIGIT/PVRIG pathway, and the PD-1/PD-L1 axis. Their lead programs, such as domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1), are being evaluated in late-stage clinical trials for various solid tumors. Arcus has established a significant strategic partnership with Gilead Sciences to co-develop and co-commercialize its portfolio.